Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 374 across all filing types
Latest filing 2025-01-08 Board/Management Inform…
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Immunovia AB (Publ) presents Nomination Committee
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a Nomination Committee for the upcoming 2025 Annual General Meeting. It details the members of the committee and their purpose, which is to prepare proposals for the board and auditors. Since this is a corporate governance announcement regarding board composition and committee formation, and does not fit into specific financial reporting categories like 10-K or ER, it is best classified as a general regulatory filing or governance-related announcement. Given the options, 'RNS' (Regulatory Filings) is the most appropriate fallback for this type of corporate announcement.
2025-01-08 English
Immunovia AB (Publ) presenterar valberedningen
AGM Information Classification · 1% confidence The document is a press release from Immunovia AB dated January 8, 2025, announcing the composition of the company's Nomination Committee ('valberedningen'). The text explicitly states that the committee will prepare proposals for the 2025 Annual General Meeting ('årsstämman 2025'), including nominations for the board and recommendations for director remuneration. This content directly relates to the governance and preparatory work for the Annual General Meeting. While it is an announcement, the subject matter is highly specific to AGM preparation and governance structure, making 'AGM Information' (AGM-R) the most appropriate fit, as it concerns materials/information related to the AGM process, even if it's not the final presentation itself. It is more specific than a general 'Governance Information' (CGR) or a general 'Regulatory Filing' (RNS).
2025-01-08 Swedish
Immunovia AB (Publ) presents Nomination Committee
Board/Management Information Classification · 1% confidence The document is a press release dated January 8, 2025, announcing the appointment of the members of the Company's Nomination Committee. The text explicitly states that this committee will prepare proposals for shareholder approval at the '2025 Annual General Meeting (AGM),' including nominating candidates for the Board and recommending compensation. While the content relates to the AGM, the document itself is an announcement about the formation of a preparatory committee for the AGM, not the AGM materials (AGM-R) or the proxy statement (DEF 14A/PSI). Since it is an announcement regarding governance structure and preparation for a future shareholder meeting, it fits best under Board/Management Information (MANG) as it details the composition of a key governance body (the Nomination Committee), or potentially Regulatory Filings (RNS) as a general corporate announcement. Given the specific focus on the composition and mandate of the Nomination Committee, which directly impacts board structure and future AGM proposals, MANG is a strong fit, although RNS is a safe fallback. However, since the committee's primary function is to nominate directors and set compensation for the board, which is closely related to management/board structure, MANG is chosen over the general RNS category. The document is short and is an announcement, not a detailed report.
2025-01-08 English
The exercise period for warrants of series TO 2 beings today
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the commencement of an exercise period for warrants (series TO 2). It details the subscription price, exercise period, dilution impact, and instructions for shareholders to exercise their warrants. This falls under the category of capital changes and share issuance activities, specifically related to the exercise of warrants which results in the issuance of new shares.
2025-01-02 English
Nyttjandeperioden för teckningsoptioner av serie TO 2 inleds idag
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Immunovia AB announcing the commencement of the exercise period for warrants (series TO 2). It details the terms of the warrants, the exercise period, subscription price, and instructions for shareholders to exercise their rights. This falls under the category of capital structure changes and share issuance activities, specifically related to the exercise of warrants, which is best classified as a share issue/capital change announcement.
2025-01-02 Swedish
Nyttjandeperioden för teckningsoptioner av serie TO 2 inleds idag
Capital/Financing Update Classification · 1% confidence The document is a press release ("PRESSMEDDELANDE") dated January 2, 2025, announcing the start of the exercise period for warrants (teckningsoptioner av serie TO 2). It details the terms of the exercise, including the subscription price, volume, expected proceeds (approx. 57.2 MSEK), shareholder commitments, and dilution effects. This type of announcement, focusing on the mechanics and timing of a capital-raising instrument (warrants), fits best under 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it pertains specifically to a financing event.
2025-01-02 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.